This study is for patients that have suffered a femur fracture due to metastatic cancer. The standard of care for this type of fracture is to stabilize the bone with an intramedullary nail. When preparing the femur for the nail, pressure can cause fat to enter the bloodstream and travel to the heart, causing heart and lung complications. The procedure being investigated in this study is called reduced pressure reaming. In this procedure the surgeon will use a device with suction when preparing the bone for the nail in order to decrease pressure and decrease the amount of fat that enters the bloodstream. Patients will be randomly assigned to either the standard preparation (standard reaming), or the reduced pressure preparation (reduced pressure reaming). After surgery, both treatment groups will followed according to standard practices at 2 weeks, 6 weeks, 3 months, and 6 months.
As our bodies use the sugars that we consume for energy they generate waste chemicals known as metabolites. One such group of metabolites is known as advanced glycation end products or AGEs for short. Critically apart from their production as a result of sugar breakdown, AGE levels in the body are also increased by the foods that we eat and when we do not get enough exercise. AGEs may cause many of the side effects experienced by prostate cancer survivors. This study aims to examine the effects of diet change and exercise on AGE levels in prostate cancer survivors.
TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.
This research study is for patients who have xerostomia (dry mouth) caused by radiation treatment received in the past for cancer.
The purposed of this study is to determine whether or not acupuncture can improve symptoms related to dry mouth due to head/neck radiotherapy.
Eligible participants will be randomized (assigned by a computer) to one of three groups: the standard of care group (group where usual care for dry mouth is given) or to one of two acupuncture groups. One of the acupuncture treatment approaches has not been studied in a large randomized trial and may not target symptoms. Each group is equally important in the trial. All groups play an important role in helping to determine if acupuncture helps decrease symptoms of dry mouth.
Participation will last up to 9 months. About 240 people will be enrolled in this trial.
Patients who have had lung cancer and are experiencing anxiety and possibly shortness of breath may be eligible to participate in the this study.
If you take part in this study, you will be randomized into one of the three study groups described below. Randomization means that you are put into a group by chance. It is like flipping a coin. You will have an equal chance of being placed in any group.
Group A: Will receive a device that will gradually slow down breathing rate. It plays music through headphones and has a sensor that attaches to your abdomen or chest. You will be asked to use it once per day for 15 minutes, at least 5 days per week, for 12 weeks.
Group B: Will receive a device that will gradually slow down breathing rate. It plays music through headphones and has a sensor that attaches to your abdomen or chest. You will be asked to use it twice per day for 15 minutes, at least 5 days per week, for 12 weeks.
Group C: Will receive a device that will leave your breathing rate at a similar rate that you usually breathe. It plays chimes through headphones and has a sensor that attaches to your abdomen or chest. You will be asked to use it once per day for 15 minutes, at least 5 days a week for 12 weeks.
Study participation lasts about 12 weeks.
The study is being done to test how well nifurtimox works against neuroblastoma and medulloblastoma in children. Early observation and testing suggest that nifurtimox has effect against these types of cancer. Nifurtimox is well tolerated by children and doesn't seem to have long term side effects when used to treat Chagas' disease. The goal of the study is to learn if nifurtimox in combination with other chemotherapy drugs is effective in shrinking/killing neuroblastoma and medulloblastoma cells.